Federal prosectors filed a new charge Friday against former Turing Pharmaceuticals CEO Martin Shkreli claiming he hid control of shares in another company he used to head, according to a Reuters report. In addition to eight criminal counts, federal prosecutors allege Shkreli sought to hide from investors his control over unrestricted shares of Retrophin Inc. , where he had also served as CEO. According to the new indictment, Shkreli and Retrophin outside counsel Evan Greebel divided control of 2 million unrestricted shares in such a way as as to avoid reporting requirements.Earlier in May, prosecutors were considering the additional charge with regard to the Retrophin shares.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.